Characteristics of Adenosine-to-Inosine RNA editing-based subtypes and novel risk score for the prognosis and drug sensitivity in stomach adenocarcinoma

Stomach adenocarcinoma (STAD) is always characterized by high mortality and poor prognosis with drug resistance and recrudescence due to individual genetic heterogeneity. Adenosine-to-Inosine RNA editing (ATIRE) has been reported associated with multiple tumors but the potential connection between ATIRE-related signatures and STAD remains unclear. In this study, we comprehensively elevated the genetic characteristics of ATIRE in STAD patients and first screened five vital survival-related ATIRE sites to identify a novel ATIRE-Risk score. Based on the risk scores, we further divided the patients into two different subtypes with diverse clinical characteristics and immune landscapes including immune cell infiltration (ICI), tumor microenvironment (TME), and immune checkpoint expression analysis. The low-risk subgroups, associated with better survival prognosis, were characterized by activated immune-cells, higher immune scores in TME, and down-expression of immunotherapy checkpoints. Moreover, different expressional genes (DEGs) between the above subtypes were further identified and the activation of immune-related pathways were found in low-risk patients. The stratified survival analysis further indicated patients with low-risk and high-tumor mutation burden (TMB) exhibited the best prognosis outcomes, implying the role of TMB and ATIRE-Risk scores was synergistic for the prognosis of STAD. Interestingly, anti-tumor chemotherapeutic drugs all exhibited lower IC50 values in low-risk subgroups, suggesting these patients might obtain a better curative response from the combined chemotherapy of STAD. Finally, combined with classical clinical features and ATIRE-Risk scores, we successfully established a promising nomogram system to accurately predict the 1/3/5-years survival ratio of STAD and this model was also estimated with high diagnostic efficiency and stable C-index with calibration curves. These significant ATIRE sites are promising to be further explored and might serve as a novel therapeutic target for STAD treatment.

[1]  Ru-yue Tian,et al.  Identification and validation of prognostic autophagy-related genes associated with immune microenvironment in human gastric cancer , 2022, Aging.

[2]  S. Kang,et al.  Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study , 2022, BMC cancer.

[3]  Ling-fang He,et al.  A novel cuproptosis-related lncRNA nomogram to improve the prognosis prediction of gastric cancer , 2022, Frontiers in Oncology.

[4]  Ping Shang,et al.  Pyroptosis-related genes play a significant role in the prognosis of gastric cancer , 2022, World journal of clinical cases.

[5]  F. Lordick,et al.  Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Ziqi Chen,et al.  Development of Tumor Mutation Burden-Related Prognostic Model and Novel Biomarker Identification in Stomach Adenocarcinoma , 2022, Frontiers in Cell and Developmental Biology.

[7]  Shuhua Li,et al.  DNA Methylation: An Important Biomarker and Therapeutic Target for Gastric Cancer , 2022, Frontiers in Genetics.

[8]  Jingjing Pan,et al.  Characteristics of the Immune Cell Infiltration Landscape in Gastric Cancer to Assistant Immunotherapy , 2022, Frontiers in Genetics.

[9]  Chuan Xiao,et al.  Construction of a ceRNA Network and Analysis of Tumor Immune Infiltration in Pancreatic Adenocarcinoma , 2021, Frontiers in Molecular Biosciences.

[10]  Robert F. Gruener,et al.  oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data , 2021, Briefings Bioinform..

[11]  Xiaochen Bo,et al.  clusterProfiler 4.0: A universal enrichment tool for interpreting omics data , 2021, Innovation.

[12]  F. D. De Braud,et al.  Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy , 2021, ESMO open.

[13]  Shuhong Zhao,et al.  rMVP: A Memory-efficient, Visualization-enhanced, and Parallel-accelerated Tool for Genome-wide Association Study , 2020, bioRxiv.

[14]  S. Park,et al.  Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer , 2020, Frontiers in Oncology.

[15]  H. Lee,et al.  Tumor immune response and immunotherapy in gastric cancer , 2019, Journal of pathology and translational medicine.

[16]  John A. Bohlin,et al.  Statistical predictions with glmnet , 2019, Clinical Epigenetics.

[17]  M. E. Norhaizan,et al.  Curcumin Combination Chemotherapy: The Implication and Efficacy in Cancer , 2019, Molecules.

[18]  Min Liu,et al.  A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients , 2019, Medicine.

[19]  Michael J Whitehead,et al.  MyelinJ: an ImageJ macro for high throughput analysis of myelinating cultures , 2019, Bioinform..

[20]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[21]  J. Lunceford,et al.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.

[22]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[23]  Zhongheng Zhang,et al.  Overview of model validation for survival regression model with competing risks using melanoma study data. , 2018, Annals of translational medicine.

[24]  Joon-Oh Park,et al.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer , 2018, Nature Medicine.

[25]  Ash A. Alizadeh,et al.  Profiling Tumor Infiltrating Immune Cells with CIBERSORT. , 2018, Methods in molecular biology.

[26]  Zhongheng Zhang,et al.  Drawing Nomograms with R: applications to categorical outcome and survival data. , 2017, Annals of translational medicine.

[27]  Leng Han,et al.  Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. , 2017, Genome research.

[28]  Yuanyu Wu,et al.  Progress in the treatment of advanced gastric cancer , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[29]  K. Haustermans,et al.  Gastric cancer , 2016, The Lancet.

[30]  K. Nishikura,et al.  A-to-I editing of coding and non-coding RNAs by ADARs , 2015, Nature Reviews Molecular Cell Biology.

[31]  Yasuhiro Aoki,et al.  RNA Editing Modulates Human Hepatic Aryl Hydrocarbon Receptor Expression by Creating MicroRNA Recognition Sequence* , 2015, The Journal of Biological Chemistry.

[32]  Leng Han,et al.  The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. , 2015, Cancer cell.

[33]  Yan Guo,et al.  Advanced Heat Map and Clustering Analysis Using Heatmap3 , 2014, BioMed research international.

[34]  Jean-François Dartigues,et al.  Estimating and comparing time‐dependent areas under receiver operating characteristic curves for censored event times with competing risks , 2013, Statistics in medicine.

[35]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[36]  Trey Ideker,et al.  Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..

[37]  S. Maas,et al.  Molecular diversity through RNA editing: a balancing act. , 2010, Trends in genetics : TIG.

[38]  M. Catarci,et al.  Perioperative Chemotherapy for Gastric Cancer , 2008, Annals of Surgical Oncology.

[39]  M. Naumann Pathogenicity island-dependent effects of Helicobacter pylori on intracellular signal transduction in epithelial cells. , 2005, International journal of medical microbiology : IJMM.

[40]  S. Love,et al.  Survival Analysis Part II: Multivariate data analysis – an introduction to concepts and methods , 2003, British Journal of Cancer.

[41]  T. Hakulinen,et al.  A computer program package for relative survival analysis. , 1985, Computer programs in biomedicine.